Works matching Isoniazid (drug interactions)

Results: 21

Drug–Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection.

Published in:

Clinical Pharmacokinetics, 2022, v. 61, n. 3, p. 339, doi. 10.1007/s40262-021-01098-8

By:

Marzolini, Catia;
Gibbons, Sara;
van Oosterhout, Joep J.;
Khoo, Saye

Publication type:

Article

Pharmacokinetics and Drug‐Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping.

Published in:

Clinical Pharmacology & Therapeutics, 2021, v. 109, n. 4, p. 1034, doi. 10.1002/cpt.2044

By:

Gausi, Kamunkhwala;
Wiesner, Lubbe;
Norman, Jennifer;
Wallis, Carole L.;
Onyango‐Makumbi, Carolyne;
Chipato, Tsungai;
Haas, David W.;
Browning, Renee;
Chakhtoura, Nahida;
Montepiedra, Grace;
Aaron, Lisa;
McCarthy, Katie;
Bradford, Sarah;
Vhembo, Tichaona;
Stranix‐Chibanda, Lynda;
Masheto, Gaerolwe R.;
Violari, Avy;
Mmbaga, Blandina T.;
Aurpibul, Linda;
Bhosale, Ramesh

Publication type:

Article

Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.

Published in:

2014

By:

Bertrand, Julie;
Verstuyft, Céline;
Chou, Monidarin;
Borand, Laurence;
Chea, Phalla;
Nay, Kuy Huong;
Blanc, François-Xavier;
Mentré, France;
Taburet, Anne-Marie;
CAMELIA (ANRS 1295-CIPRA KH001) Study Group

Publication type:

journal article

Dependence of Efavirenz- and Rifampicin-Isoniazid–Based Antituberculosis Treatment Drug-Drug Interaction on CYP2B6 and NAT2 Genetic Polymorphisms: ANRS 12154 Study in Cambodia.

Published in:

Journal of Infectious Diseases, 2014, v. 209, n. 3, p. 399, doi. 10.1093/infdis/jit466

By:

Bertrand, Julie;
Verstuyft, Céline;
Chou, Monidarin;
Borand, Laurence;
Chea, Phalla;
Nay, Kuy Huong;
Blanc, François-Xavier;
Mentré, France;
Taburet, Anne-Marie

Publication type:

Article

Lethal drug interaction: Isoniazid and methylxanthines.

Published in:

Drug Development Research, 1986, v. 9, n. 4, p. 299, doi. 10.1002/ddr.430090407

By:

Harris, Cynthia M.;
Springfield, Angela C.;
Ranschaert, Erik R.;
Lal, Harbans

Publication type:

Article

PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid.

Published in:

Pharmaceutical Research, 2021, v. 38, n. 9, p. 1485, doi. 10.1007/s11095-021-03095-9

By:

Balhara, Ankit;
Singh, Saranjit

Publication type:

Article

Drug Interaction between Rifampicin, Isoniazid and Cotrimoxazole in Rabbits.

Published in:

Human & Experimental Toxicology, 1992, v. 11, n. 2, p. 105, doi. 10.1177/096032719201100208

By:

Malhi, R.;
Uppal, R.;
Sharma, P.L.

Publication type:

Article

Transbuccal Delivery of Isoniazid: Ex Vivo Permeability and Drug-Surfactant Interaction Studies.

Published in:

AAPS PharmSciTech, 2020, v. 21, n. 8, p. 1, doi. 10.1208/s12249-020-01827-5

By:

Kroth, Roselene;
Argenta, Débora Fretes;
Conte, Julia;
Amaral, Beatriz Ribeiro;
Caon, Thiago

Publication type:

Article

Clinically significant interactions with drugs used in the treatment of tuberculosis.

Published in:

2002

By:

Yew, W.;
Yew, W W

Publication type:

journal article

Use of Oral Anticoagulants in Older Patients.

Published in:

Drugs & Aging, 2000, v. 16, n. 6, p. 409, doi. 10.2165/00002512-200016060-00003

By:

Sebastian, J.L.;
Tresch, D.D.

Publication type:

Article

Oxcarbazepine Induced Maculopapular Rash - A Case Report.

Published in:

2015

By:

BISWAS, ARUNAVA;
MITRA, RITABRATA;
SEN, SUKANTA;
PAL, AGNIK;
TRIPA THI, SANTANU KUMAR

Publication type:

Case Study

Formulation and In Vitro Evaluation of Rifampicin Loaded Porous Microspheres.

Published in:

Scientia Pharmaceutica, 2010, v. 78, n. 2, p. 291, doi. 10.3797/scipharm.0910-09

By:

Bhise, Satish Balakrishna;
More, Avinash Bhanudas;
Malayandi, Rajkumar

Publication type:

Article

Clinical Evaluation of the Nelfinavir-Rifabutin Interaction in Patients with Tuberculosis and Human Immunodeficiency Virus Infection.

Published in:

Pharmacotherapy, 2007, v. 27, n. 6, p. 793, doi. 10.1592/phco.27.6.793

By:

Benator, Debra A.;
Weiner, Marc H.;
Burman, William J.;
Vernon, Andrew A.;
Zhao, Zhen A.;
Khan, Awal E.;
Jones, Brenda E.;
Sandman, Laurie;
Engle, Meliss;
Silva-Trigo, Claudia;
Hsyu, Poe H.;
Becker, Mark I.;
Peloquin, Charles A.

Publication type:

Article

The evaluation of the anti‐cancer drug elesclomol that forms a redox‐active copper chelate as a potential anti‐tubercular drug.

Published in:

IUBMB Life, 2019, v. 71, n. 5, p. 532, doi. 10.1002/iub.2002

By:

Ngwane, Andile H.;
Petersen, Ray‐Dean;
Baker, Bienyameen;
Wiid, Ian;
Wong, Ho Ning;
Haynes, Richard K.

Publication type:

Article

Prophylaxis of Mycobacterial Infections in Immunocompromised Patients.

Published in:

American Family Physician, 1996, v. 54, n. 6, p. 1981

By:

Krance, Mary Beth;
Fisher, Melanie Ann

Publication type:

Article

Evaluation of the Drug Interaction between Rifabutin and Efavirenz in Patients with HIV Infection and Tuberculosis.

Published in:

Clinical Infectious Diseases, 2005, v. 41, n. 9, p. 1343

By:

Weiner, Marc;
Benator, Debra;
Peloquin, Charles A.;
Burman, William;
Vernon, Andrew;
Engle, Melissa;
Khan, Awal;
Zhao, Zhen

Publication type:

Article

Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention.

Published in:

2021

By:

Podany, A T;
Leon-Cruz, J;
Hakim, J;
Supparatpinyo, K;
Omoz-Oarhe, A;
Langat, D;
Mwelase, N;
Kanyama, C;
Gupta, A;
Benson, C A;
Chaisson, R E;
Swindells, S;
Fletcher, C V;
Team, the AIDS Clinical Trials Group A5279;
AIDS Clinical Trials Group A5279 Team

Publication type:

journal article

Investigations on the Influence of Zidovudine in the Pharmacokinetics of Isoniazid and Its Hepatotoxic Metabolites in Rats.

Published in:

Journal of Pharmacy Practice, 2019, v. 32, n. 1, p. 9, doi. 10.1177/0897190017735424

By:

Ramanathan, Raghu;
Sivanesan, Karthikeyan

Publication type:

Article

Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda: a qualitative study.

Published in:

2021

By:

Zakumumpa, Henry;
Kitutu, Freddy Eric;
Ndagije, Helen Byomire;
Diana, Nakitto-Kesi;
Ssanyu, Jacquellyn Nambi;
Kiguba, Ronald

Publication type:

journal article

Molecular Docking and ADMET Modelling in the Design of New Targeted Anti-tuberculosis Drug.

Published in:

Malaysian Journal of Medicine & Health Sciences, 2024, v. 20, p. 1

By:

Dianel Mohd Tazizi, Mohammad Hafizie;
Suhaimi, Ahmad Marwazi;
Wahab, Habibah A.;
Gazzali, Amirah Mohd

Publication type:

Article

A patient with HIV and tuberculosis with diminished clopidogrel response.

Published in:

2014

By:

Metzger, Nicole L;
Momary, Kathryn M

Publication type:

journal article